Fig. 6From: A novel small molecule glycolysis inhibitor WZ35 exerts anti-cancer effect via metabolic reprogrammingWZ35 caused a significant disturbance in the cellular metabolic state. A and D ECAR and OCR was measured with Seahorse XF96 Flux analyzer in HCCLM3 cells. B and C Glycolytic capacity and maximal glycolytic capacity reserve were measured in non-glucose medium after the addition of glucose (10 mM), oligomycin (1 μM) and 2-DG (100 mM). E–G Basal respiration, maximal respiration and ATP production were measured after the injection of oligomycin (1 μM), FCCP (0.5 μM) and AA/Rot (2 μM). H The glucose concentration of culture medium was detected by hexokinase method. I The absorption of glucose was measured in combination with CCK-8 assay in either non-glucose-treated or low glucose-treated or high glucose-treated or high glucose plus 2-DG-treated HCCLM3 cells with or without treatment of WZ35. J The contents of metabolic products in HCCLM3 cells treated with or without WZ35 (10 μg/mL). All these results have been presented as the mean ± standard error from independent experiments in triplicate. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, student’s t test. K Proposed working model showed distinct metabolic changes after drug actionBack to article page